FYB Share Price Performance
€0
-46.50 (-100.00%)
Price €0
Fair Value€35.69
Share Pricen/a
Formycon AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
FYB Community Narratives
AN
Fair Value €35.69 35.1% undervalued intrinsic discount
New Approvals And Regional Expansion Will Create Future Opportunities
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
New Approvals And Regional Expansion Will Create Future Opportunities
Key Takeaways Waiving the Phase III study for FYB206 cuts significant R&D costs, improving net margins and freeing capital for other uses. Strategic regional expansions and targeted product introductions, like the FYB201 syringe, boost market penetration and revenue potential.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
€35.69
35.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
22.08% p.a.
Profit Margin
28.59%
Future PE
26.63x
Share price in 2028
€54.66
Recently Updated Narratives
AN
New Approvals And Regional Expansion Will Create Future Opportunities
Fair Value: €35.69 35.1% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Formycon AG Key Details
About FYB
- Founded
- 1999
- Employees
- 245
- CEO
- WebsiteView website
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin’s lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
